Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma
- PMID: 17544585
- DOI: 10.1016/j.ctrv.2007.04.007
Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma
Abstract
Epstein-Barr virus (EBV) is constantly present in undifferentiated and poorly-differentiated nasopharyngeal cancer. Thus, tumour-associated viral antigens are potential targets for immunotherapy. Recently, both preclinical and early clinical studies have shown that various strategies can enhance EBV-specific immunity. Moreover, significant anti-tumour effect has been observed, and was generally correlated with biological response. The present review discusses the rational for EBV-targeted immunotherapy and summarises the latest developments in this area.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
